cept Therapeutics rporated(CORT) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - The company's revenue for 2025 was $761 million, an increase from $675 million in the previous year, with a revenue guidance for 2026 set at $900 million to $1 billion [3][4] - Net income for 2025 was $99.7 million, down from $141.2 million in the prior year [3] Business Line Data and Key Metrics Changes - The Cushing's syndrome business saw a 37% increase in tablets delivered compared to 2024, with a record number of new prescriptions and first-time prescribers [11][12] - Despite a 61% increase in new prescriptions, the gap between new prescriptions and tablets sold indicates capacity issues with the pharmacy vendor [11] Market Data and Key Metrics Changes - The transition to a new specialty pharmacy began in October 2025, aimed at addressing capacity issues and improving service delivery [12][55] - The company expects its Cushing's syndrome business to grow to at least $2 billion in annual revenue by the end of the decade, driven by increased recognition of hypercortisolism [14][26] Company Strategy and Development Direction - The company plans to appeal the FDA's decision regarding relacorilant and aims to make it available to patients as quickly as possible [10][26] - The focus remains on cortisol modulation to treat serious diseases, with ongoing research in oncology and metabolic conditions [15][21] Management's Comments on Operating Environment and Future Outlook - Management expressed surprise at the FDA's decision not to approve relacorilant, citing strong clinical trial data and alignment with FDA guidance during development [9][10] - The company is optimistic about the future growth of its Cushing's syndrome business and the potential for relacorilant to enhance treatment options [14][26] Other Important Information - The company reported cash and investments of $532 million as of December 31, 2025, reflecting stock repurchase activities [4] - The ROSELLA trial demonstrated a 35% reduction in risk of death for patients receiving relacorilant in combination with nab-paclitaxel, with a median overall survival increase of 4.1 months [19][20] Q&A Session Summary Question: Thoughts on the CRL and FDA's decision - Management believes the FDA may have shifted its expectations and plans to seek clarification in an upcoming meeting [34][38] Question: Guidance assumptions regarding Korlym - The net price for Korlym through the AG is about a 30% discount, with expectations for pricing pressures in 2026 [40] Question: Likelihood of running a randomized trial for relacorilant - Management indicated that the identification and treatment of hypercortisolism is crucial, but the path forward in clinical development remains uncertain [41][42] Question: Confidence in resolving supply chain issues - The transition to a new pharmacy partner has shown promising results, with improvements in service delivery metrics [55][56] Question: Safety profile of relacorilant - The safety profile remains consistent with previous analyses, showing no significant increases in ALT levels compared to nab-paclitaxel alone [60][62] Question: Impact of KEYTRUDA on treatment options - Management noted that KEYTRUDA's approval is limited by biomarker expression, but there is interest in maintaining treatment options for patients [64]